ORTHOPEDIATRICS CORP
32c38eb6617549149c9e4d9990bb4ea9
PRODUCTION_VERIFIED schema v3.0.0 Inferred last heartbeat: 2026-07-23T17:39:34.067565+00:00

Business Model Classification Tokens

contract_cycle_length
null
Inferred
Pending — BM Dev Shop classification run
enterprise_sales_motion
null
Inferred
Pending — BM Dev Shop classification run
procurement_complexity
null
Inferred
Pending — BM Dev Shop classification run
vendor_lock_coefficient
null
Inferred
Pending — BM Dev Shop classification run
base_product_margin
null
Inferred
Pending — BM Dev Shop classification run
consumable_margin
null
Inferred
Pending — BM Dev Shop classification run
switching_cost_architecture
null
Inferred
Pending — BM Dev Shop classification run
consumable_repurchase_frequency
null
Inferred
Pending — BM Dev Shop classification run
blade_dependency_coefficient
null
Inferred
Pending — BM Dev Shop classification run
bundle_discount_depth
null
Inferred
Pending — BM Dev Shop classification run
cross_sell_attach_rate
null
Inferred
Pending — BM Dev Shop classification run
bundle_churn_vs_single_churn
null
Inferred
Pending — BM Dev Shop classification run
bundle_margin_blended
null
Inferred
Pending — BM Dev Shop classification run
upsell_pathway_architecture
null
Inferred
Pending — BM Dev Shop classification run

Business Model Archetype Classification

University of St. Gallen — 55 Business Model Navigator (Gassmann et al.)

SG-035 Premium WHO High
Direct: pricing_architecture=Premium niche pricing justified by pediatric-specific design IP; vulnerable to GPO contract pressure and hospital cost-containment; ASP erosion risk ~3-5% annually. Corroborated: target_gross_margin_bracket=73.1% Gross Margin (Premium (>60%)) (High gross margin bracket (>60%) indicates premium positioni)
SG-006
Cash Machine
VALUE High
SG-053
Two-sided Market
HOW High
SG-013
Experience Selling
WHAT High
SG-040
Razor and Blade
VALUE High
SG-036
Product to Capability
WHAT High
SG-049
Subscription
VALUE High

Hybrid Combination

Premium (SG-035) WHO provides the core structure, combined with Cash Machine (SG-006) + Two-sided Market (SG-053) + Experience Selling (SG-013) to form the complete business model fingerprint.

55 Archetypes Evaluated High: 7 Medium: 23 Registry: schemas/sg55_archetype_registry.yaml

Knowledge Graph — All Sections

debt_leverage_profile
0.31x Total Debt / Equity (Conservative)
High
SEC-XBRL
interest_rate_sensitivity
Moderate sensitivity; ~$150M debt load at variable rates means 200bps rise adds ~$3M annual interest expense, pressuring thin EBITDA margins
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Single-use orthopedic implant components sourced from specialized metal fabricators in Germany and titanium suppliers concentrated in China/Japan
Inferred
Agent_Inference
international_expansion_readiness
EUR, GBP, AUD exposure across Europe/Australia; ~25% international revenue faces 5-15% devaluation headwind annually, partially unhedged
Inferred
Agent_Inference
geographic_footprint
Primary markets: EU (EUR), UK (GBP), Australia (AUD); sovereign devaluation risk moderate given USD-denominated contracts partially offset local currency billing
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Moderate lock-in; proprietary implant-specific tooling from 2-3 specialized contract manufacturers likely exceeds 30% input cost with 12-18 month switching lead time
Inferred
Agent_Inference
business_model_type_primary
Medical device manufacturer/distributor; cloud dependency minimal—ERP and sales systems disruption manageable within 30 days via migration or backup
Inferred
Agent_Inference
business_model_type_secondary
Secondary software/enabling technology (surgical planning tools); cloud termination would disrupt digital planning platforms but not core implant revenue stream
Inferred
Agent_Inference
switching_cost_profile
Low API coupling risk; primary revenue is physical devices, not software APIs; surgeon training and proprietary instrumentation systems create stickiness without API dependency
Inferred
Agent_Inference
howey_test_risk_index
Very low Howey Test risk; revenue model is product sales of FDA-regulated medical devices, not investment contracts or profit-sharing schemes
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Moderate GDPR exposure via EU patient data in surgical planning software; CCPA exposure limited; compliance infrastructure present but smaller company scale means audit risk
Inferred
Agent_Inference
antitrust_exposure_flag
Low antitrust risk; operates in fragmented pediatric orthopedics niche with <5% global market share; no dominant position triggering regulatory scrutiny
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
~85% transactional (per-procedure implant sales), ~15% recurring (instrument sets, service agreements); minimal true subscription revenue base
Inferred
Agent_Inference
monetization_vector
Per-procedure consumable implant sales with instrument set loans; revenue tied directly to surgical volume at hospital and ASC customers
Inferred
Agent_Inference
pricing_architecture
Premium niche pricing justified by pediatric-specific design IP; vulnerable to GPO contract pressure and hospital cost-containment; ASP erosion risk ~3-5% annually
Inferred
Agent_Inference
pricing_power_rating
6/10; pediatric specialization provides modest pricing power vs. adult orthopedics competitors, but hospital procurement and GPO dynamics cap premium to ~15-20% above adult implant pricing
Inferred
Agent_Inference
target_gross_margin_bracket
73.1% Gross Margin (Premium (>60%))
High
SEC-XBRL
churn_vulnerability_index
Low free-rider risk; proprietary instrumentation systems create surgeon dependency; competitor switching requires retraining and new instrument investment, reducing churn
Inferred
Agent_Inference
headcount_cost_structure
Revenue growth is near-linear to headcount in field sales/distribution; direct sales force expansion required proportionally with geographic penetration; limited leverage until scale
Inferred
Agent_Inference
marginal_cost_of_growth
High marginal cost of growth; each new territory requires dedicated sales rep, instrument inventory ($50-100K/set), and surgeon training investment before revenue generation
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; company operates direct sales model, not franchise network
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC likely improves via brand recognition and GPO relationships, but surgeon training bottleneck and instrument set capital requirements constrain unit economics improvement
Inferred
Agent_Inference
network_effect_present
Weak network effects; surgeon community word-of-mouth within pediatric orthopedics subspecialty provides modest referral benefit but no true platform network effect
Inferred
Agent_Inference
asset_efficiency_ratio
-7.7% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Tier 2 recession resistance; pediatric orthopedic procedures (scoliosis, fractures) are largely non-elective, providing ~70% volume stability; elective cases defer in downturns
Inferred
Agent_Inference
customer_segment_primary
Pediatric orthopedic surgeons at children's hospitals and academic medical centers; top 10 hospital systems likely represent 20-25% of revenue
Inferred
Agent_Inference
customer_segment_secondary
Ambulatory surgery centers and community hospital orthopedic departments handling pediatric cases; growing segment as procedures shift to lower-cost outpatient settings
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
4.7% CapEx / Revenue (Low-CapEx Asset-Light)
High
SEC-XBRL
sec_cik
0001425450
High
SEC-EDGAR
ticker
KIDS
High
SEC-EDGAR

Business Model Components

Core Space

> *Pending Turn 2 — Business Model Type Agent population.*

Interaction Modes

> *Pending Turn 2 — Business Model Type Agent population.*

Product Matrix

> *Pending Turn 2 — Business Model Type Agent population.*

Historical Evolution Log

Live Operational Signals

Signal DateSignal TypeSummary
Source

Evaluation Gate — Persona Stress Tests

SKILL_BUFFETT_VAL_03PASS2026-07-23no unmet atoms among this persona's authored questions
SKILL_LEGAL_SEC_01PASS2026-07-23no unmet atoms among this persona's authored questions
SKILL_SHORT_BEAR_01PASS2026-07-23no unmet atoms among this persona's authored questions
SKILL_MACRO_STRAT_01PASS2026-07-23no unmet atoms among this persona's authored questions
SKILL_OPS_PARTNER_01PASS2026-07-23no unmet atoms among this persona's authored questions

Live Status

No Live Status block found.